Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus

[1]  David J. Topham,et al.  Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies , 2018, Cell.

[2]  Y. Kawaoka,et al.  Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. , 2017, The Journal of infection.

[3]  Y. Kawaoka,et al.  Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies , 2017, Scientific Reports.

[4]  S. Subramaniam,et al.  Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes , 2017, Nature Microbiology.

[5]  M. Kiso,et al.  A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release , 2017, EBioMedicine.

[6]  Zhu Guo,et al.  An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo. , 2016, Antiviral research.

[7]  J. Powers,et al.  Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model , 2016, mBio.

[8]  P. Wilson,et al.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. , 2016, The Journal of clinical investigation.

[9]  A. Monto,et al.  Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. , 2015, The Journal of infectious diseases.

[10]  M. Eichelberger,et al.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase , 2015, Journal of Virology.

[11]  J. Ravetch,et al.  The role of Fc–FcγR interactions in IgG-mediated microbial neutralization , 2015, The Journal of experimental medicine.

[12]  M. Eichelberger,et al.  Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers , 2015, Nature Communications.

[13]  M. Eichelberger,et al.  An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. , 2014, Journal of virological methods.

[14]  J. Ravetch,et al.  Type I and type II Fc receptors regulate innate and adaptive immunity , 2014, Nature Immunology.

[15]  Antoine M. van Oijen,et al.  Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization , 2013, PloS one.

[16]  Szabina Fodor,et al.  Neutrophil cell surface receptors and their intracellular signal transduction pathways , 2013, International immunopharmacology.

[17]  A. Mantovani,et al.  Serum Amyloid P Is a Sialylated Glycoprotein Inhibitor of Influenza A Viruses , 2013, PloS one.

[18]  Luigi Calzolai,et al.  Rational Engineering of a Human Anti-Dengue Antibody through Experimentally Validated Computational Docking , 2013, PloS one.

[19]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[20]  Ryo Takano,et al.  Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. , 2011, Virus research.

[21]  Eiryo Kawakami,et al.  Seroprevalence of Pandemic 2009 (H1N1) Influenza A Virus among Schoolchildren and Their Parents in Tokyo, Japan , 2011, Clinical and Vaccine Immunology.

[22]  J. Yewdell,et al.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of Experimental Medicine.

[23]  Albert D. M. E. Osterhaus,et al.  Recombinant Soluble, Multimeric HA and NA Exhibit Distinctive Types of Protection against Pandemic Swine-Origin 2009 A(H1N1) Influenza Virus Infection in Ferrets , 2010, Journal of Virology.

[24]  K. Ikuta,et al.  Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors , 2009, Biochemical and Biophysical Research Communications.

[25]  A. Fomsgaard,et al.  The evolution of human influenza A viruses from 1999 to 2006: A complete genome study , 2008, Virology Journal.

[26]  J. Skehel,et al.  Variation and infectivity neutralization in influenza , 2006, Immunology.

[27]  Guang-Wu Chen,et al.  Genomic Signatures of Human versus Avian Influenza A Viruses , 2006, Emerging infectious diseases.

[28]  Sang Joon Kim,et al.  A Mathematical Theory of Communication , 2006 .

[29]  H. Klenk,et al.  Neuraminidase Is Important for the Initiation of Influenza Virus Infection in Human Airway Epithelium , 2004, Journal of Virology.

[30]  A. Dalton,et al.  An Electron Microscope Study , 2003 .

[31]  J. Taubenberger,et al.  Influenza A virus neuraminidase: regions of the protein potentially involved in virus-host interactions. , 2000, Virology.

[32]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[33]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  I. Mellman,et al.  Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG‐transporting placental epithelium. , 1989, The EMBO journal.

[35]  S. Cusack,et al.  Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.

[36]  G. Air,et al.  Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. , 1985, Virology.

[37]  L. Gerace,et al.  Phosphorylation of the nuclear lamins during interphase and mitosis. , 1985, The Journal of biological chemistry.

[38]  J. Oxford,et al.  An investigation of antigenic drift of neuraminidases of influenza A (H1N1) viruses , 1984, Journal of Hygiene.

[39]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[40]  G. Trinchieri,et al.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. , 1983, Journal of immunology.

[41]  G. Air,et al.  Amino acid sequence changes in antigenic variants of type A influenza virus N2 neuraminidase. , 1982, Virology.

[42]  W G Laver,et al.  Molecular mechanisms of variation in influenza viruses , 1982, Nature.

[43]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[44]  C W Potter,et al.  Determinants of immunity to influenza infection in man. , 1979, British medical bulletin.

[45]  R. Compans,et al.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. , 1974, Virology.

[46]  A. Monto,et al.  Effect of neuraminidase antibody on Hong Kong influenza. , 1973, Lancet.

[47]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[48]  R. Chanock,et al.  Association of serum anti-neuraminidase antibody with resistance to influenza in man. , 1972, The New England journal of medicine.

[49]  F. S. Chang,et al.  Functional Significance of Sialidase During Influenza Virus Multiplication: an Electron Microscope Study , 1969, Journal of virology.

[50]  E. D. Kilbourne,et al.  Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice , 1968, Journal of virology.

[51]  R. Webster,et al.  Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. , 1967, Journal of immunology.